Media headlines about ArQule (NASDAQ:ARQL) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ArQule earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 47.5632598153477 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- ArQule (ARQL) Rating Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- Cytokinetics (CYTK) vs. ArQule (ARQL) Head-To-Head Comparison (americanbankingnews.com)
- A Look at Target Price and Valuation of Arqule Inc (ARQL) – ExpertGazette (expertgazette.com)
- ArQule, Inc. (ARQL) to achieve 10.00% EPS growth for next year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- ArQule, Inc. (ARQL) receives consensus rating of 2.30 – Nasdaq Fortune (press release) (nasdaqfortune.com)
Shares of ARQL stock traded up $0.44 on Wednesday, reaching $2.87. 2,456,796 shares of the company’s stock were exchanged, compared to its average volume of 371,265. The company has a current ratio of 4.98, a quick ratio of 4.98 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $202.10, a PE ratio of -7.36 and a beta of 1.43. ArQule has a one year low of $0.92 and a one year high of $2.94.
Several analysts recently commented on ARQL shares. Needham & Company LLC upgraded shares of ArQule from a “hold” rating to a “buy” rating in a research note on Thursday, December 14th. Roth Capital started coverage on shares of ArQule in a research note on Thursday, February 22nd. They issued a “buy” rating and a $5.00 price objective for the company. Zacks Investment Research cut shares of ArQule from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. B. Riley started coverage on shares of ArQule in a research note on Friday, February 2nd. They issued a “buy” rating and a $3.00 price objective for the company. Finally, ValuEngine upgraded shares of ArQule from a “sell” rating to a “hold” rating in a research note on Thursday, March 15th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. ArQule presently has an average rating of “Buy” and an average target price of $3.50.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by BBNS and is owned by of BBNS. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/2018/03/21/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-arqule-arql-stock-price/2030152.html.
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.